Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study Presented at ASCO
Safety and Single-Agent Activity Support Development of Panzem(R) NCD as a Combination Therapy for Glioblastoma Multiforme ROCKVILLE, Md., June 05, 2007 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflam...Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
Safety, Efficacy and Markers Demonstrated in Combination Trial ROCKVILLE, Md., June 06, 2007 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics primarily for the treatment of cancer and inflammatory diseases, announced the presentation of int...EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
... Multiple Mechanisms for panzem NCD, MKC-1, and ENMD-1198 Highlighted at Oncology Drug Discovery Conference ROCKVILLE, Md., March 26, 2007 /PRNewswire-FirstCall/ -- EntreMed, Inc., ...EntreMed Reports Third Quarter 2008 Financial Results
...penses for the third quarter declined versus the prior quarters in 2008 due in part to the decision made earlier in the year to discontinue the use of panzem in oncology, but also impacted by a decreasing number of patients being treated with MKC-1 related to Phase 2 trials initiated in 2006 and 2007. We ex...